Fig 1.
Venn diagram showing size and overlap of study populations in the Norwegian Women and Cancer (NOWAC) study, the NOWAC Post-genome cohort and the Clinical and Multi-omic (CAMO) cohort.
Fig 2.
Timeline of the study period showing year of breast cancer diagnosis of the study participants (dots), as well as notable changes in screening, diagnostic, and treatment regimes in Norway (vertical lines). Line A denotes the introduction of the national breast cancer (BC) screening program, line B the introduction of chemotherapy regimens AC and FEC in the Norwegian national guidelines for BC treatment, line C the introduction of HER2 analysis in BC diagnostics, line D the use of paclitaxel and docetaxel, aromatase inhibitor, and adjuvant trastuzumab in BC treatment, and line E the introduction of Ki67 analysis and change of ER cutoff to 1% in BC diagnostics. The time periods of data collection in the NOWAC study are shown as colored, horizontal bars. Abbreviations: AC = doxorubicin (also known as Adriamycin) and cyclophosphamide; ER = estrogen receptor; FEC = 5-fluorouracil, epirubicin and cyclophosphamide.
Table 1.
Number of CAMO study participants with pre- or post-diagnostic information from baseline and follow-up questionnaires.
Fig 3.
Overview of sample sizes, data sources, and data types.
The Clinical and Multi-omic (CAMO) cohort, nested within the Norwegian Women and Cancer (NOWAC) study, provides multiple types of data from a wide range of sources, thereby enabling a systems epidemiology approach to breast cancer. These multimodal data may be combined in various ways to create complex study designs that can be used to investigate hypotheses related to breast cancer prevention, diagnostics, treatment, and survival.
Table 2.
Comparison of selected characteristics between the study populations of CAMO (n = 388) and NOWAC breast cancer cases (n = 10 356).
Table 3.
Clinical characteristics of the participants in the CAMO cohort (n = 388).